OncoMatch/Clinical Trials/NCT06380660
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Is NCT06380660 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies ACE-86225106 tablet for solid tumor, adult.
Treatment: ACE-86225106 tablet — The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Ovarian Cancer
Breast Carcinoma
Prostate Cancer
Disease stage
Metastatic disease required
Advanced solid tumors, difficult to treat or intolerant to standard treatment, suitable for investigational treatment; Has measurable disease per RECIST 1.1, castration-resistant prostate cancer (CRPC) patients can be assessed according to PCWG3
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-cancer drugs
Exception: protocol-defined wash-out period
Receiving any anti-cancer drugs, major surgery, extensive radiation therapy, or local radiation therapy within protocol-defined wash-out period
Lab requirements
Blood counts
adequate bone marrow function
Kidney function
adequate organ function
Liver function
adequate organ function
Adequate organ function and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify